Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Repros Therapeutics Inc    RPRX

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Repros Therapeutics Inc : NASDAQ:RPRX and NASDAQ:AMRN added to Biotech Stock Watch List

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2013 | 03:40pm CEST

New York, NY - Growing Stock Report initiates a NASDAQ Biotech Stock Watch List adding Repros Therapeutics Inc. (NASDAQ:RPRX) and Amarin Corporation plc (NASDAQ:AMRN).

Repros Therapeutics Inc. (NASDAQ:RPRX) a development stage biopharmaceutical company that engages in the development of new drugs to treat hormonal and reproductive system disorders is currently up (+70.54%) today on over 88,000,000 shares traded after the drug developer said its potential low testosterone treatment Androxal met both goals mandated by the Food and Drug Administration in a late-stage trial. Repros Therapeutics Inc. (NASDAQ:RPRX) said Wednesday after markets closed that initial results from the study showed that more than enough patients taking the drug had total testosterone levels that fell within a normal range at the end of 12 weeks of treatment. This news and increase in the stock price has prompted Growing Stock Report to add Repros Therapeutics Inc. (NASDAQ:RPRX) to their NASDAQ Biotech Stock Watch List.

To see what other Investors are saying about Repros Therapeutics Inc. (NASDAQ:RPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=RPRX&SubId=AW

Amarin Corporation plc (NASDAQ:AMRN) a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases is currently up (+3.39%) after bouncing off it's recent 52 week low of $6.77 after a recent report that said weekly Vascepa prescription growth is decelerating at a time when it should be doing the opposite. The number of patients going back for Vascepa refills is also lower than expected. Total Vascepa prescriptions were 1,240, up 14% from the week of March 8. Numerically, Vascepa scripts are growing but the rate of growth has dropped for four weeks straight. Week-over-week script growth was 33% for the week ended Feb. 22, down to 14% for the week of March 15. This bounce in Amarin Corporation plc (NASDAQ:AMRN) has prompted Growing Stock Report to add the stock to their NASDAQ Biotech Stock Watch List.

To see what other Investors are saying about Amarin Corporation plc (NASDAQ:AMRN)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=AMRN&SubId=AW

Also mentioned in their NASDAQ Biotech Stock Watch List was Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) which is currently up (+1.89%) as of this writing.

To see what other Investors are saying about Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=KERX&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REPROS THERAPEUTICS INC
04/20 REPROS THERAPEUTICS : Patent Issued for Trans-Clomiphene and Its Analogues as Ag..
04/17 REPROS THERAPEUTICS INC. (NASDAQ : RPRX) Files An 8-K Regulation FD Disclosure
04/17 REPROS THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
04/17 Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using ..
04/13 REPROS THERAPEUTICS INC. (NASDAQ : RPRX) Files An 8-K Departure of Directors or ..
04/13 REPROS THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
04/10 REPROS THERAPEUTICS INC. (NASDAQ : RPRX) Files An 8-K Regulation FD Disclosure
04/10 Repros Names Larry Dillaha, M.D., its Permanent President and CEO
04/10 REPROS THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
04/10 Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of ..
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
04/17 Repros nabs new patent covering uterine disorder med Proellex
04/10 FDA continues partial clinical hold for Repros Therapeutics' fibroids drug
03/31 Repros Therapeutics beats by $0.01
02/02 New chief at Repros
01/25 HEALTHCARE - TOP 5 GAINERS / LOSERS : 30 am
Advertisement
Financials ($)
Sales 2017 -
EBIT 2017 -21,3 M
Net income 2017 -21,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 0
Capitalization 26,9 M
More Financials
Chart REPROS THERAPEUTICS INC
Duration : Period :
Repros Therapeutics Inc Technical Analysis Chart | RPRX | US76028H2094 | 4-Traders
Full-screen chart
Technical analysis trends REPROS THERAPEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 5,25 $
Spread / Average Target 420%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry M. Dillaha President, Chief Executive Officer & Director
Patrick P. Fourteau Chairman
Katherine A. Anderson CFO, Secretary & Chief Accounting Officer
Joachim F. Wernicke Chief Medical Officer
Daniel F. Cain Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REPROS THERAPEUTICS IN..-23.48%27
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG6.92%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results